Abstract
In ulcerative colitis, mucosal healing has clearly been incorporated in the assessment of treatment efficacy. In Crohn’s disease, this concept has only emerged in recent clinical trials with biological therapies. Systemic steroids don’t reliably induce mucosal healing in Crohn’s disease, but purine analogues and anti-TNF agents have a potential to heal mucosal ulcerations. Evidence for mucosal healing has now been provided for the anti-TNF agents infliximab, adalimumab and certolizumab pegol. For infliximab in Crohn’s disease, mucosal healing has been associated with a reduction in clinical relapses, disease-related hospitalizations and surgeries. On the contrary, the benefit of treating asymptomatic patients with IBD more intensively until they achieve mucosal healing has not been proven. In clinical practice, assessing mucosal healing should be considered in patients with persistent symptoms despite adequate therapy as well as in patients where treatment discontinuation is being considered.
Keywords: Crohn’s disease, endoscopy, endpoint, ibd, inflammatory bowel disease, medical therapy, mucosal healing, outcome, ulcerative colitis, anti-TNF agents, endpoint, purine analogues.
Current Drug Targets
Title:Medical Therapy and Mucosal Healing
Volume: 13 Issue: 10
Author(s): Marc Ferrante and Gert Van Assche
Affiliation:
Keywords: Crohn’s disease, endoscopy, endpoint, ibd, inflammatory bowel disease, medical therapy, mucosal healing, outcome, ulcerative colitis, anti-TNF agents, endpoint, purine analogues.
Abstract: In ulcerative colitis, mucosal healing has clearly been incorporated in the assessment of treatment efficacy. In Crohn’s disease, this concept has only emerged in recent clinical trials with biological therapies. Systemic steroids don’t reliably induce mucosal healing in Crohn’s disease, but purine analogues and anti-TNF agents have a potential to heal mucosal ulcerations. Evidence for mucosal healing has now been provided for the anti-TNF agents infliximab, adalimumab and certolizumab pegol. For infliximab in Crohn’s disease, mucosal healing has been associated with a reduction in clinical relapses, disease-related hospitalizations and surgeries. On the contrary, the benefit of treating asymptomatic patients with IBD more intensively until they achieve mucosal healing has not been proven. In clinical practice, assessing mucosal healing should be considered in patients with persistent symptoms despite adequate therapy as well as in patients where treatment discontinuation is being considered.
Export Options
About this article
Cite this article as:
Ferrante Marc and Van Assche Gert, Medical Therapy and Mucosal Healing, Current Drug Targets 2012; 13 (10) . https://dx.doi.org/10.2174/138945012802429679
DOI https://dx.doi.org/10.2174/138945012802429679 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Role of Angiogenesis Inhibitors in Colorectal Cancer: Sensitive and Insensitive Tumors
Current Cancer Drug Targets Review of Chemoradiotherapy for High-Risk Prostate Cancer
Reviews on Recent Clinical Trials Molecular Pathways Linking Inflammation and Cancer
Current Molecular Medicine Functional Food: Product Development and Health Benefits
Recent Patents on Engineering Kinases as Drug Targets in Inflammation: In Vitro and In Vivo Target Validation and Expression Profiling
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry An Overview of Phytotherapeutic Approaches for the Treatment of Benign Prostatic Hyperplasia
Mini-Reviews in Medicinal Chemistry Targeted Enzyme Prodrug Therapies
Mini-Reviews in Medicinal Chemistry Pattern of Medication Use Among Older Inpatients in Seven Hospitals in Italy: Results from the Criteria to Assess Appropriate Medication Use Among Elderly Complex Patients (CRIME) Project
Current Drug Safety Post-translational and Post-transcriptional Modifications of Pregnane X Receptor (PXR) in Regulation of the Cytochrome P450 Superfamily
Current Drug Metabolism Anti PD-1 and PDL-1 Immunotherapy in the Treatment of Advanced Non- Small Cell Lung Cancer (NSCLC): A Review on Toxicity Profile and its Management
Current Drug Safety Neuroinflammation and Immunity: A New Pharmacological Target in Depression
CNS & Neurological Disorders - Drug Targets Current Perspectives on the Role of Nrf2 in 5-Fluorouracil Resistance in Colorectal Cancer
Anti-Cancer Agents in Medicinal Chemistry Opioids Resistance in Chronic Pain Management
Current Neuropharmacology Subject Index to Volume 9
Current Pharmaceutical Design Gene Polymorphisms and Pharmacogenetics in Rheumatoid Arthritis
Current Genomics Strategies that Target Tight Junctions for Enhanced Drug Delivery
Current Pharmaceutical Design Circulating Advanced Oxidation Protein Products as Oxidative Stress Biomarkers and Progression Mediators in Pathological Conditions Related to Inflammation and Immune Dysregulation
Current Medicinal Chemistry Interleukin-21 in Immune and Allergic Diseases
Inflammation & Allergy - Drug Targets (Discontinued) Editorial [Immunogenicity of Biotherapeutics: A Need for Consensus on Flexibility of Approach (Guest Editor: Stewart Barker)]
Current Drug Safety Focus on Ulcerative Colitis: Stable Gastric Pentadecapeptide BPC 157
Current Medicinal Chemistry